Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe

Clinical Chemistry

Volumn 49, Issue 4, 2003, Pages 669-672

  Imhof, Armin ^a   Fröhlich, Margit ^a   Loewel, Hannelore ^b   Helbecque, Nicole ^c   Woodward, Mark ^d   Amouyel, Phillipe ^c   Lowe, Gordon D O ^e   Koenig, Wolfgang ^a  

^a UNIVERSITY OF ULM   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c INSTITUT PASTEUR DE LILLE   (France)

^d UNIVERSITY OF SYDNEY   (Australia)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; EUROPE; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; MALE; NORMAL HUMAN; PARTICLE ENHANCED IMMUNONEPHELOMETRIC ASSAY; POPULATION DISTRIBUTION; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT; TECHNIQUE;

ADOLESCENT; ADULT; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; EUROPE; FEMALE; HUMANS; IMMUNOASSAY; MALE; MASS SCREENING; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; REFERENCE VALUES; TIME FACTORS;

EID: 0037379955     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.4.669     Document Type: Article

References (30)

1. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
2. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994;15:81-8.
3. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
4. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999;19:3071-8.
5. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584-90.
6. Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001;21:603-10.
7. Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Despres JP, et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 2001;161:2474-80.
8. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
9. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 2001;47:28-30.
10. Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000;46:934-8.
11. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-41.
12. Fröhlich M, Döring A, Imhof A, Hutchinson WL, Pepys MB, Koenig W. Oral contraceptive use is associated with a systemic acute phase response. Fibrinolysis Proteolysis 1999;13:239-44.
13. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100:717-22.
14. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-6.
15. van Baal WM, Kenemans P, van der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CD. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999;81:925-8.
16. Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001;357:763-7.
17. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 1988;41:105-14.
18. Hoffmeister A, Rothenbacher D, Bäzner U, Fröhlich M, Brenner H, Hombach V, et al. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 2001;87:262-6.
19. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
20. Kluft C, de Maat MP. Determination of the habitual low blood level of C-reactive protein in individuals. Ital Heart J 2001;2:172-80.
21. Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
22. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001;32:2575-9.
23. Koenig W. C-reactive protein and cardiovascular risk: has the time come for screening the general population? Clin Chem 2001;47:9-10.
24. Koenig W, Pepys MB. C-reactive protein risk prediction: low specificity, high sensitivity. Ann Intern Med 2002;136:550-2.
25. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996;312:1061-5.
26. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 2001;153:1183-90.
27. Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998;44:1358-61.
28. WHO Expert Committee on Biological Standardization. WHO Expert Committee on Biological Standardization 37th report. In: WHO Technical Report Series 760. Geneva: WHO, 1987:21-2.
29. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K, et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000;355:688-700.
30. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.